ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell [Seeking Alpha]
ResMed Inc. (RMD)
Last resmed inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.resmed.com/investor-relations/default.aspx
Company Research
Source: Seeking Alpha
I rate RMD a strong sell due to the imminent threat from Apnimed's oral OSA drug AD109, which showed 47% efficacy in Phase 3 trials. AD109, if FDA-approved and adopted, could disrupt RMD's device-centric model by offering a simpler, more patient-friendly alternative as early as 2027. RMD's current valuation appears fair under the status quo but faces a high risk of sharp correction if the new pill reaches the market. Joey Ingelhart/iStock via Getty Images Intro ResMed ( RMD ) is a $37 billion powerhouse that sees itself as a "36-year-old startup" in the field of sleep and breathing health. It dominates as the #1 provider in 140+ countries with a 50–60% market share in sleep apnea devices like CPAP (“Continuous Positive Airway Pressure”) machines, masks, and This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I w
Show less
Read more
Impact Snapshot
Event Time:
RMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RMD alerts
High impacting ResMed Inc. news events
Weekly update
A roundup of the hottest topics
RMD
News
- Sleep device maker ResMed ramps up doctor outreach to tap Ozempic surge [Yahoo! Finance]Yahoo! Finance
- ResMed Inc. (RMD): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- ResMed (NYSE:RMD) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- ResMed (NYSE:RMD) had its price target raised by analysts at Wells Fargo & Company from $265.00 to $270.00. They now have an "equal weight" rating on the stock.MarketBeat
- ResMed (NYSE:RMD) was given a new $281.00 price target on by analysts at Robert W. Baird.MarketBeat
RMD
Earnings
- 1/29/26 - Beat
RMD
Sec Filings
- 2/4/26 - Form 144
- 2/4/26 - Form 144
- 2/3/26 - Form 4
- RMD's page on the SEC website